CytRx Corp (CYTR) Posts Q2 Loss of 28c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to CytRx Corp (CYTR) Posts Q2 Loss of 28c/Share
August 7, 2014 11:28 AM EDT
Aegis Capital affirms its Buy rating and $12 target price on CytRx Corp. (Nasdaq: CYTR) following Q2 results and update.
Analyst Ram Selvaraju commented, The firm ended the quarter with $102.5mm in cash, which we expect to be sufficient to fund operations well into 2016, past a... More
August 7, 2014 6:09 AM EDT
CytRx (Nasdaq: CYTR) announced that its oral presentation given by Sant P. Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center, titled Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas, was featured in The Lancet Oncology in its July 2014 issue (Volume 15, Issue 8) in a review of the major presentations from the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.
We are honored to have been included in The Lancet Oncologys... More
